Danaher Corporation (NYSE:DHR) Shares Sold by Csenge Advisory Group

Csenge Advisory Group trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 6.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,815 shares of the conglomerate’s stock after selling 245 shares during the period. Csenge Advisory Group’s holdings in Danaher were worth $713,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. FAS Wealth Partners Inc. increased its holdings in shares of Danaher by 20.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate’s stock worth $2,203,000 after buying an additional 1,639 shares during the last quarter. Asahi Life Asset Management CO. LTD. acquired a new stake in shares of Danaher during the 1st quarter worth $539,000. Horizon Financial Services LLC increased its holdings in shares of Danaher by 20,400.0% during the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate’s stock worth $1,681,000 after buying an additional 8,160 shares during the last quarter. Vision Capital Management Inc. acquired a new stake in shares of Danaher during the 1st quarter worth $461,000. Finally, Eos Management L.P. increased its holdings in shares of Danaher by 55.8% during the 1st quarter. Eos Management L.P. now owns 40,567 shares of the conglomerate’s stock worth $8,316,000 after buying an additional 14,537 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of DHR stock opened at $189.98 on Monday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70. The company’s 50-day simple moving average is $196.13 and its 200-day simple moving average is $204.86. The stock has a market capitalization of $135.96 billion, a price-to-earnings ratio of 36.89, a PEG ratio of 2.67 and a beta of 0.77.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The business had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.58 billion. Equities analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.67%. Danaher’s payout ratio is 24.85%.

Insider Activity

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the firm’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares of the company’s stock, valued at $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Christopher Paul Riley sold 15,805 shares of the firm’s stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president directly owned 15,179 shares in the company, valued at $3,005,442. This represents a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of research reports. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, April 23rd. Evercore ISI decreased their price target on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. Leerink Partners upped their price target on shares of Danaher from $225.00 to $230.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 23rd. JPMorgan Chase & Co. decreased their price target on shares of Danaher from $280.00 to $260.00 and set an “overweight” rating for the company in a research report on Tuesday, April 22nd. Finally, The Goldman Sachs Group decreased their price target on shares of Danaher from $260.00 to $240.00 and set a “neutral” rating for the company in a research report on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $248.48.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.